Genmab Reports 87% Response in EPCORE NHL-2 Lymphoma Trial

Genmab A/S is advancing multiple clinical trials targeting various cancers, including lymphoma, advanced solid tumors, metastatic solid tumors, and hematologic malignancies. Notably, their EPCORE NHL-2 trial combining Epcoritamab with R-ICE chemotherapy showed an 87% overall response rate and 65% complete response in patients with diffuse large B-cell lymphoma, highlighting a promising treatment for high-risk patients. Additionally, Genmab is investigating several experimental drugs such as GEN1286 for advanced solid tumors, GEN1042 in combination with radiotherapy and pembrolizumab for metastatic tumors (in partnership with BioNTech SE), and GEN1056 for patients lacking standard care options. The ongoing Phase 1/2 trial of GEN3014 (HexaBody®-CD38) in relapsed or refractory multiple myeloma aims to evaluate safety and efficacy compared to existing therapies like daratumumab. These studies are at various stages, with some actively recruiting and others progressing toward completion, which could significantly impact Genmab’s market position and investor confidence if positive results continue. Overall, Genmab’s broad oncology pipeline and collaborations underscore its potential to introduce novel cancer therapies and strengthen its competitive edge in the biotech sector.